What Amylyx Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 19 | 39 |
| Total trades | 28 | 60 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 276,976 | 1,453,246 |
| Disposed | 361,302 | 831,975 |
| Net activity | −84,326 | +621,271 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Frates James M | Chief Financial Officer | Nov 10 | Open-market sale · S | −7,200 | $30.97 | −$223K | 233,625 |
| Frates James M | Chief Financial Officer | Nov 10 | Open-market sale · S | −12,800 | $30.32 | −$388K | 240,825 |
| Frates James M | Chief Financial Officer | Nov 10 | Exercise / conversion · M | +20,000 | $6.88 | +$138K | 253,625 |
| Cohen Joshua B | Co-Chief Executive Officer | Nov 09 | Open-market sale · S | −61,895 | $30.11 | −$1.86M | 3,513,123 |
| Cohen Joshua B | Co-Chief Executive Officer | Nov 09 | Open-market sale · S | −38,105 | $29.39 | −$1.12M | 3,575,018 |
| Frates James M | Chief Financial Officer | Nov 09 | Open-market sale · S | −12,300 | $30.11 | −$370K | 233,625 |
| Frates James M | Chief Financial Officer | Nov 09 | Open-market sale · S | −7,700 | $29.39 | −$226K | 245,925 |
| Frates James M | Chief Financial Officer | Nov 09 | Exercise / conversion · M | +20,000 | $6.88 | +$138K | 253,625 |
| Klee Justin B. | Co-Chief Executive Officer | Nov 09 | Open-market sale · S | −62,517 | $30.11 | −$1.88M | 3,513,056 |
| Klee Justin B. | Co-Chief Executive Officer | Nov 09 | Open-market sale · S | −37,483 | $29.39 | −$1.1M | 3,575,573 |
| Milne George M Jr | Director | Oct 05 | Open-market sale · S | −30,000 | $27.70 | −$831K | 782,881 |
| Frates James M | Chief Financial Officer | Sep 10 | Open-market sale · S | −1,042 | $33.23 | −$34.6K | 233,625 |
| Frates James M | Chief Financial Officer | Sep 10 | Open-market sale · S | −9,768 | $32.27 | −$315K | 234,667 |
| Klee Justin B. | Co-Chief Executive Officer | Sep 10 | Open-market sale · S | −1,439 | $33.16 | −$47.7K | 3,613,056 |
| Klee Justin B. | Co-Chief Executive Officer | Sep 10 | Open-market sale · S | −29,025 | $32.13 | −$933K | 3,614,495 |
| Cohen Joshua B | Co-Chief Executive Officer | Sep 10 | Open-market sale · S | −919 | $33.15 | −$30.5K | 3,613,123 |
| Cohen Joshua B | Co-Chief Executive Officer | Sep 10 | Open-market sale · S | −29,545 | $32.16 | −$950K | 3,614,042 |
| Bedrosian Camille L | Chief Medical Officer | Sep 10 | Open-market sale · S | −2,081 | $33.09 | −$68.9K | 278,064 |
| Bedrosian Camille L | Chief Medical Officer | Sep 10 | Open-market sale · S | −7,947 | $32.21 | −$256K | 280,145 |
| Mazzariello Gina | Chief Legal Officer | Sep 10 | Open-market sale · S | −11 | $33.34 | −$367 | 190,838 |
Loading...